Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III ...

US cardiorenal-focussed drugmaker Ardelyx (Nasdaq: ARDX) announced that Mike Kelliher, formerly executive vice president, ...

Texas-based ImmunoPrecise Antibodies (Nasdaq :IPA) a leader in AI-driven biotherapeutics, closed 22% higher Thursday. The ...

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the ...

China-based Kelun-Biotech Biopharmaceutical (6990: HK) announced the placement of 5,918,000 H shares under its general ...

Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the ...

US biotech Trevi Therapeutics (Nasdaq: TRVI) has raised around $115 million in a public stock offering, giving it fresh ...

US gene therapy company RegeNXBio (Nasdaq: RGNX) yesterday announced new positive interim data from the Phase I/II AFFINITY ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

Headquartered in Munich, Germany, the company aims to address unmet medical needs in ophthalmology through proprietary gene ...

Japan’s Otsuka (TYO: 4578) today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of ...